LILLY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.
Drugs and US Patents for LILLY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | HISTAMINE PHOSPHATE | histamine phosphate | INJECTABLE;INJECTION | 000734-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-003 | Mar 7, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-001 | Jul 10, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | PENICILLIN G POTASSIUM | penicillin g potassium | INJECTABLE;INJECTION | 060384-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | QUINIDINE GLUCONATE | quinidine gluconate | INJECTABLE;INJECTION | 007529-002 | Feb 10, 1989 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 062565-002 | Apr 4, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LILLY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | RE39050 | ⤷ Try a Trial |
Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-003 | Dec 24, 2003 | 5,229,382*PED | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,731,342 | ⤷ Try a Trial |
Lilly | GEMZAR | gemcitabine hydrochloride | INJECTABLE;INJECTION | 020509-002 | May 15, 1996 | 5,464,826*PED | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,747,510 | ⤷ Try a Trial |
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-004 | Aug 3, 2004 | 5,508,276*PED | ⤷ Try a Trial |
Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-008 | Feb 14, 2005 | 5,658,590*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
International Patents for LILLY Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 1732629 | ⤷ Try a Trial |
South Korea | 100763051 | ⤷ Try a Trial |
China | 1933864 | ⤷ Try a Trial |
China | 100581607 | ⤷ Try a Trial |
Croatia | P20191242 | ⤷ Try a Trial |
Denmark | 1732628 | ⤷ Try a Trial |
Japan | 2007530241 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LILLY Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2365988 | 2018C/006 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
0933372 | 13/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 |
2782584 | 21C1058 | France | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406 |
0273658 | SPC/GB05/003 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811 |
1480644 | 16C1019 | France | ⤷ Try a Trial | PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628 |
1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
0584952 | SPC/GB98/048 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.